Compile Data Set for Download or QSAR
Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 10997
TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582528(US11524945, Compound Gefitinib)
Affinity DataKd:  110nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM5446(Erlotinib | OSI-774 | N-(3-ethynylphenyl)-6,7-bis(...)
Affinity DataKd:  310nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM5446(Erlotinib | OSI-774 | N-(3-ethynylphenyl)-6,7-bis(...)
Affinity DataKd:  430nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582529(US11524945, Compound Erlotinib-4-methylphenyl anal...)
Affinity DataKd:  745nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582536(US11524945, Compound 8 (Csbl-2))
Affinity DataKd:  922nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582532(US11524945, Compound 4 (cmpd#4))
Affinity DataKd:  1.15E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582532(US11524945, Compound 4 (cmpd#4))
Affinity DataKd:  1.55E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582529(US11524945, Compound Erlotinib-4-methylphenyl anal...)
Affinity DataKd:  1.55E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582535(US11524945, Compound 7 (cmpd-#7))
Affinity DataKd:  2.45E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582530(US11524945, Compound 1 (Csbl-1))
Affinity DataKd:  2.77E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582528(US11524945, Compound Gefitinib)
Affinity DataKd:  4.51E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582535(US11524945, Compound 7 (cmpd-#7))
Affinity DataKd:  6.59E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582533(US11524945, Compound 1 New (cmpd#1new))
Affinity DataKd:  6.85E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582534(US11524945, Compound 2 New (cmpd#2new))
Affinity DataKd:  8.00E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582536(US11524945, Compound 8 (Csbl-2))
Affinity DataKd:  8.84E+3nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582533(US11524945, Compound 1 New (cmpd#1new))
Affinity DataKd:  1.27E+4nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582530(US11524945, Compound 1 (Csbl-1))
Affinity DataKd:  1.77E+4nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent

TargetIntegrin-linked protein kinase(Human)
The Cleveland Clinic Foundation

US Patent
LigandPNGBDBM582531(US11524945, Compound 3 (cmpd#3))
Affinity DataKd:  4.96E+4nMAssay Description:Thus, while these compounds were extensively used in studying ILK-mediated cellular and disease processes, their reported inhibitory effects are prob...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2023
Entry Details
Go to US Patent